- Cutting-edge Facilities: Bright Green operates a state-of-the-art facility in Grants, New Mexico, boasting over 1 million square feet of space dedicated to research, production, and manufacturing of plant-based drugs.
- Multidisciplinary Team: We have assembled a diverse team of medical professionals, researchers, horticultural experts, and production professionals, fostering collaboration and innovation in botanical drug discovery.
- Comprehensive Portfolio: Our R&D program encompasses a diverse range of Schedule I and Schedule II plant-based drugs, including Psilocybin, Peyote, Opium Poppy, and more.
- Compliance and Regulation: The R&D division adheres to strict regulatory standards and compliance protocols, ensuring that all research activities are conducted in accordance with local, state, and federal laws.
- Clinical Trials: As part of our strategic roadmap, Bright Green will deploy comprehensive clinical trials to evaluate the safety and efficacy of its botanical medications, paving the way for FDA approval and commercialization.
- Formulation Development: The R&D team explores various formulations and delivery methods to optimize the therapeutic benefits of plant-based drugs, including oral, topical, and inhalation routes of administration. We are committed to pushing the boundaries of drug research to continuously uncover new insights into the therapeutic potential of plant-based compounds.
- Strategic Partnerships: The company collaborates with leading academic institutions, research organizations, and industry partners to accelerate R&D efforts and bring innovative medications to market.
- Scale-Up Capabilities: With its large-scale manufacturing facility, Bright Green has the capacity to scale up production of plant-based drugs to meet growing demand and market needs.
- Patient-Centric Focus: Above all else, Bright Green’s endeavors are driven by a commitment to improving patient outcomes and enhancing quality of life through the development of safe, effective, and accessible botanical medications.
